+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp



Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp



ChemoTherapy 50(4): 202-210



Combination therapy is used to widen the antimicrobial spectrum, minimize toxicity and prevent the emergence of resistant mutants. Synergy between levofloxacin or ciprofloxacin and ceftazidime, cefepime, imipenem, piperacillin-tazobactam and amikacin was evaluated by checkerboard assay with 55 strains and by time-kill curves with 8 strains of Pseudomonas aeruginosa and Acinetobacter spp. In the checkerboard assay, synergy and additivity were the most frequent effects observed among all the combinations against P. aeruginosa and Acinetobacter spp., with no significant differences between the two fluoroquinolones. No antagonism was observed. In the time-kill curves, synergy was evidenced against all the tested strains, at least for one combination at one of the time points considered. Levofloxacin and ciprofloxacin combined with ceftazidime, as well as levofloxacin plus amikacin, were synergistic for all the strains tested. Combinations of fluoroquinolones with beta-lactams or amikacin show an enhanced activity against P. aeruginosa and Acinetobacter spp.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011726281

Download citation: RISBibTeXText

PMID: 15452399

DOI: 10.1159/000081033


Related references

Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagnostic Microbiology & Infectious Disease 44(1): 35-41, 2002

Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrobial Agents and ChemoTherapy 40(3): 772-775, 1996

Synergistic activity of gentamicin, ciprofloxacin, and levofloxacin in combination with cefepime and piperacillin/tazobactam against P aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 170-171, 2001

Comparison of in vitro activities of levofloxacin, ciprofloxacin, ceftazidime, cefepime, imipenem, and piperacillin-tazobactam against aerobic bacterial pathogens from patients with nosocomial infections. Journal of Microbiology, Immunology, and Infection 40(2): 134-140, 2007

Comparative antibacterial activities of meropenem , imipenem , ceftazidime , piperacillin/tazobactam , ciprofloxacin and tobramycin , singly and in combination against resistant and susceptible isolates of Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35: 104, 1995

Activity of piperacillin/tazobactam in combination with amikacin , trovafloxacin , and ciprofloxacin against Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 289, 1999

Comparative bactericidal activity of imipenem , piperacillin + tazobactam , ticarcillin+clavulanic acid alone and in combination with amikacin or sulbactam against Acinetobacter baumanii with different resistance phenotypes. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 35: 103, 1995

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagnostic Microbiology & Infectious Disease 38(1): 37-41, 2000

In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. ChemoTherapy 49(6): 294-297, 2003

In vitro Activity of Combination Therapy with Cefepime, Piperacillin-Tazobactam, or Meropenem with Ciprofloxacin against Multidrug-Resistant Pseudomonas aeruginosa Strains. Chemotherapy 49(6): 294-297, 2003

In vitro synergy testing of levofloxacin, ofloxacin, and ciprofloxacin in combination with aztreonam, ceftazidime, or piperacillin against Pseudomonas aeruginosa. Diagnostic Microbiology & Infectious Disease 42(1): 75-78, 2002

Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrobial Agents and ChemoTherapy 50(6): 2228-2230, 2006

In vitro synergy testing of levofloxacin , ofloxacin , and ciprofloxacin in combination with piperacillin , ceftazidime , aztreonam , and gentamicin against Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36: 82, 1996

Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clinical Therapeutics 29(5): 889-899, 2007

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. European Journal of Clinical Microbiology & Infectious Diseases 16(2): 159-162, 1997